#United States #biopharmaceuticals #PTC Therapeutics #Warren #NASDAQ PTCT

PTC Therapeutics Inducement Grants Overview

On December 16, 2025, PTC Therapeutics, Inc. (NASDAQ: PTCT), a prominent biopharmaceutical company, disclosed that it had granted inducement awards to five new employees as part of its hiring strategy. This decision is in accordance with Nasdaq Listing Rule 5635(c)(4), which permits such inducement grants that are material to the employment acceptance. In total, the company approved stock options for 3,825 shares, along with 4,385 restricted stock units (RSUs) for the newly onboarded employees.

Details of the Inducement Grants

The approved stock option awards have been assigned an exercise price of $75.42 per share, reflecting the closing price of PTC's common stock on the grant date. The stock options come with a ten-year term and will vest over a period of four years. The vesting schedule is structured so that 25% of each employee's options will vest on the first anniversary of their hiring date, with the remaining shares vesting at a rate of 6.25% for each subsequent three-month period thereafter, contingent upon the employee's continued service with the company.

In contrast, the RSUs will vest annually over the same four-year period, with 25% vesting at each annual anniversary of the employee's hiring date, again depending on the employee's ongoing service.

PTC Therapeutics: A Brief Background

Founded with the vision of developing innovative pharmaceutical solutions, PTC Therapeutics is dedicated to making significant advancements in the treatment of rare disorders. The company aims to discover, develop, and commercialize differentiated medicines that meet unfulfilled medical needs, particularly focusing on children and adults impacted by these conditions. PTC Therapeutics prides itself on its robust pipeline that includes transformative therapies tailored to improve the lives of patients.

PTC's strategy hinges on leveraging scientific expertise and a comprehensive global commercial infrastructure. This approach not only optimizes value for patients but also enhances the overall value creation for stakeholders involved in the healthcare ecosystem.

As part of its commitment to transparency and engagement with stakeholders, PTC maintains an active online presence, offering insights into its developments through various social media platforms, including LinkedIn, X, Facebook, and Instagram. Visitors can learn more about the company's current projects and future ambitions by visiting their website at www.ptcbio.com.

Conclusion

The inducement grant by PTC Therapeutics serves as a strategic move to attract top talent in a competitive market. By offering stock options and RSUs, the company not only enhances its compensation package but also aligns employee incentives with the long-term goals of the organization. Looking ahead, PTC is poised to continue its commitment to innovation and patient-centric care, paving the way for new treatment possibilities in the realm of rare diseases.